Sanofi announces that 25 abstracts on approved and investigational drugs will be presented at the American Thoracic Society (ATS) International Conference, May 17-22 in San Diego.

Oral presentations will be made on data from Dupixent (dupilumab), in partnership with Regeneron, evaluating its potential as a treatment for patients with chronic obstructive pulmonary disease (COPD) from two landmark Phase 3 studies.

Abstracts will include the first presentation of phase 2b asthma data for rilzabrutinib, as well as an oral presentation for lunsekimig, currently in phase 2b asthma development.

''Our strong presence at this year's ATS conference highlights our innovative research into inflammatory respiratory conditions,'' says Naimish Patel, Global Head of Development, Immunology and Inflammation at Sanofi.

"Our collective data at the meeting underscores our commitment and progress in improving the lives of patients suffering from devastating respiratory diseases," he adds.

Copyright (c) 2024 CercleFinance.com. All rights reserved.